Effect of FPP on Cutaneous Barrier Integrity

Starting soon · Not applicable

Conditions studied: Skin Hydration in Healthy Volunteers

In brief

This pilot study will test how Fermented Papaya Preparation (FPP) impacts overall TEWL of areas that commonly display diminished barrier function, such as the skin from face, arms, and hands. Areas of diminished barrier function are defined as those not visible to the eye but identified as areas of high transepidermal water loss (TEWL) as measured by a non-invasive pen-like device. A TEWL value of 20 or higher at a location would be considered high TEWL. Participants will attend 5 visits over 20 weeks, with 12-weeks of FPP treatment, and 8-weeks of follow-up.

Key facts

Study ID

NCT07725835

Run by

University of Pittsburgh

People needed

30

Starts

2026-07-01

Expected to finish

2028-07-01

Last updated by the study team

2026-07-24

Who can join

Age: 50 and older, up to 75. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• 50-75 years
• Willing to allow collection of 3 blood samples (Baseline, Week 12 and Week 20)
• Willing to log daily compliance with FPP intake during the study period (12 weeks)
• Absence of active systemic disease per investigator judgement.
• No current use of immunosuppressant or immunomodulatory medications.
• No active dermatological conditions at measurement sites that could impair measure, per investigator judgement.
• Investigator determination of general good health.

You may not qualify if…

• Co-morbidity or concurrent medication that the Investigator deems impactful to patient safety or ability to adhere to FPP dosage.
• Co-morbidity or concurrent medication that the Investigator deems confounding to outcome measure (i.e., topical or systemic steroid).
• Current or history of allergy to FPP ingredients: Dextrose, Carica papaya, or Food yeast.
• Concurrent participation in another interventional trial that may impact measures, per investigator judgement.
• Uncontrolled diabetes (A1c >7%).
• Open wounds or actively receiving Wound Care services.
• Pregnant or breastfeeding women.
• Current use of warfarin.

Where it is running

• McGowan Institute for Regenerative Medicine — Pittsburgh, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.